6-氟-4-甲基-(1h)吲唑 | 105391-75-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 6-氟-4-甲基-(1h)吲唑
• 英文名称: 6-fluoro-4-methyl-1H-indazole
• CAS: 105391-75-1
• 化学式: C₈H₇FN₂
• mdl: MFCD07781480
• 分子量: 150.15
• InChiKey: PSCCMBDKQNEINU-UHFFFAOYSA-N

物化性质

• 沸点：
  290.3±20.0 °C(Predicted)
• 密度：
  1.299±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES
  申请人：Cmiljanovic Vladimir

  公开号：US20110275762A1

  公开（公告）日：2011-11-10

  The invention relates to novel therapeutic agents and diagnostic probes. The invention also relates to phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor triazine-, pyrimidine- and pyridine-based compoundŝ Formula (I), their stereoisomers, geometric isomers, tautomers, solvates, metabolites, N-oxide derivatives, pharmaceutically acceptable salts, and prodrugs thereof compositions of the new compounds; either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, for treating disorders mediated by lipid kinases. •Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. (Formula I)

  本发明涉及新型治疗剂和诊断探针。本发明还涉及磷脂酰肌醇3-激酶（PI3K）和哺乳动物雷帕霉素靶蛋白酶（mTOR）抑制剂三嗪基、嘧啶基和吡啶基化合物̂公式（I），它们的立体异构体、几何异构体、互变异构体、溶剂化物、代谢物、N-氧化衍生物、药学上可接受的盐以及前药的组合物；新化合物的组合物，可以单独使用或与至少一种额外的治疗剂结合，与药学上可接受的载体；以及使用新化合物的方法，可以单独使用或与至少一种额外的治疗剂结合，用于治疗由脂质激酶介导的疾病。公开了使用公式（I）化合物的方法，用于哺乳动物细胞中的体外、原位和体内诊断、预防或治疗这种疾病或相关病理条件。(公式I)
• SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE
  申请人：Lycera Corporation

  公开号：US20150119439A1

  公开（公告）日：2015-04-30

  The invention provides saturated acyl guanidine compounds that inhibit F 1 F 0 -ATPase, and methods of using saturated acyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

  该发明提供了饱和脂肪酰基胍化合物，可以抑制F1F0-ATP酶，并且使用饱和脂肪酰基胍化合物作为治疗剂治疗医疗障碍的方法，例如免疫障碍、炎症状况或癌症。
• INDAZOLE GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF
  申请人：Lycera Corporation

  公开号：US20150152063A1

  公开（公告）日：2015-06-04

  The invention provides indazole guanidine compounds that inhibit F 1 F 0 -ATPase, and methods of using indazole guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

  该发明提供了一种抑制F1F0-ATP酶的吲唑胍化合物，并使用吲唑胍化合物作为治疗剂治疗医学疾病，例如免疫紊乱、炎症病症或癌症的方法。
• HETEROCYCLIC KINASE INHIBITORS
  申请人：INTELLIKINE LLC

  公开号：US20140206685A1

  公开（公告）日：2014-07-24

  The present invention provides heterocyclic compounds for use as kinase inhibitors and in other applications. Also provided are pharmaceutical compositions and methods of treatments of diseases and conditions associated with P13 kinase activity.
• US8921361B2
  申请人：——

  公开号：US8921361B2

  公开（公告）日：2014-12-30